A couple months ago, genetic engineer Dr. Bong-Hee Sohn joined Kraig Biocraft’s research and development team to develop new high performance polymers using spider silk gene sequences. Dr. Sohn earned her Ph.D. from Kyung-Hee Univ. in South Korea and has extensive research background. One of her areas of expertise in genetic engineering is the development of innovative methods for transgenic silkworm production.
CEO Kim K. Thompson stated, “Dr. Sohn has already made a significant impact on the pace and direction of our development program. This is a very exciting time for the Company and for the research laboratory. The University of Notre Dame hired Dr. Sohn to work on specific applications of genetic engineering in silkworm for polymer development and protein expression platform technologies, which are the Company’s major areas of focus.”
She continued, “We would like to express our congratulations to the research team for their foresight in initiating this addition and expansion. The Company is now fully on target for significantly accelerating the pace of its R & D.”
Kraig Biocraft has focused their efforts on developing and commercializing high performance polymers using spider silk gene sequences. The company intends to tap into the $92 billion market for high performance and technical fibers. Kraig Biocraft believes that spider silk is a “super fiber” that will have numerous commercial and consumer applications.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment